Form 4: Vir Biotechnology, Inc. (VIR), Virgin Herbert, transaction 02/22/2022

Summary

Herbert Virgin, EVP, Research & CSO of Vir Biotechnology, Inc. (VIR), reports on this Form 4 the acquisition of 70,000 restricted stock units on 02/22/2022 under the issuer's Equity Incentive Plan and a new option for 70,000 shares at $29.48 expiring 02/21/2032. The same day, an option for 1,375 shares was exercised at $1.53 and 1,375 shares were sold at $30 under a Rule 10b5-1 plan adopted February 26, 2021. Direct holdings were 175,407 shares after the transactions. Howard Horn signed as Attorney-in-Fact on 02/24/2022.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Virgin Herbert (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 (Street) SAN FRANCISCO CA 94158 (City) (State) (Zip) | Virgin Herbert | (Last) | (First) | (Middle) | C/O VIR BIOTECHNOLOGY, INC. | 499 ILLINOIS STREET, SUITE 500 | SAN FRANCISCO | CA | 94158 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP, Research & CSO | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | EVP, Research & CSO
3. Date of Earliest Transaction
 (Month/Day/Year) 02/22/2022
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock | 02/22/2022 | A (1) | 70,000 | A | $ 0.00 | 175,407 | D
Common Stock | 02/22/2022 | M | 1,375 | A | $ 1.53 | 176,782 | D
Common Stock | 02/22/2022 | S (2) | 1,375 | D | $ 30 | 175,407 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Stock Option (Right to Buy) | $ 1.53 | 02/22/2022 | M | 1,375 | (3) | 01/26/2028 | Common Stock | 1,375 | $ 0.00 | 219,505 | D
Stock Option (Right to Buy) | $ 29.48 | 02/22/2022 | A | 70,000 | (4) | 02/21/2032 | Common Stock | 70,000 | $ 0.00 | 70,000 | D
Explanation of Responses:
1. Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 26, 2021.
3. The option is fully vested and exercisable.
4. 25% of the shares subject to the stock option vest and become exercisable on February 22, 2023, and the remainder vest in 36 equal monthly installments thereafter.
Remarks:
/s/ Howard Horn, Attorney-in-Fact | 02/24/2022
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_VIR_4_filed2022-02-24_0001209191-22-012952.xml

Size

19,046 bytes

SHA-256

c2ed803b2c1c45381d05e3eb2b69c7d1758d068fee084e81f688d54174646891

Our copy

SEC_VIR_4_filed2022-02-24_0001209191-22-012952.xml

Original

www.sec.gov